Pharmaceutical product for the treatment of sepsis

US6315999A · kind A · utility

Assignee

• SOLVAY SA · BE

Inventors

• Jerald C. Sadoff · Washington, US
• Steven M. Opal · Central Falls, US
• Alan Cross · Chevy Chase Section Five, US
• Mark Bodmer · South Hinksey, GB

Key dates

• Filing date: Jun 2, 1994
• Grant date: Nov 13, 2001
• Expiry date: Jun 2, 2014

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An antibody to tumor necrosis factor-.alpha. (anti-TNF) and an antibody to bacterial lipopolysaccharide (anti-LPS) used together in a neutropenic rat model of sepsis are shown to enhance survival of the rats relative to either antibody used alone. Pharmaceutical products including each of the components are therefore of utility in therapy of sepsis. The anti-LPS antibody included may be specific for the O-specific clain of a particular bacterial lipopolysaccharide (serotype specific antibody) but preferably recognizes the core glycolipid of lipopolysaccharide.